

# Resource Summary Report

Generated by [RRID](#) on Aug 2, 2026

## p53 (1C12) Mouse mAb (Alexa Fluor(R) 647 Conjugate)

RRID:AB\_2256294

Type: Antibody

---

### Proper Citation

Cell Signaling Technology Cat# 2533, RRID:AB\_2256294

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2256294](http://antibodyregistry.org/AB_2256294)

**Proper Citation:** Cell Signaling Technology Cat# 2533, RRID:AB\_2256294

**Target Antigen:** TP53

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: F. Consolidation on 10/2018: AB\_10693443, AB\_2256294.

**Antibody Name:** p53 (1C12) Mouse mAb (Alexa Fluor(R) 647 Conjugate)

**Description:** This monoclonal targets TP53

**Target Organism:** rat, mouse, human

**Antibody ID:** AB\_2256294

**Vendor:** Cell Signaling Technology

**Catalog Number:** 2533

**Record Creation Time:** 20250820T035810+0000

**Record Last Update:** 20250820T174047+0000

---

### Ratings and Alerts

No rating or validation information has been found for p53 (1C12) Mouse mAb (Alexa Fluor(R) 647 Conjugate).

No alerts have been found for p53 (1C12) Mouse mAb (Alexa Fluor(R) 647 Conjugate).

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 5 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Ingelshed K, et al. (2024) MDM2/MDMX inhibition by Sulanemadlin synergizes with anti-Programmed Death 1 immunotherapy in wild-type p53 tumors. *iScience*, 27(6), 109862.

Zaher DM, et al. (2021) A Novel Benzopyrane Derivative Targeting Cancer Cell Metabolic and Survival Pathways. *Cancers*, 13(11).

Rosu A, et al. (2021) Loss of tRNA-modifying enzyme Elp3 activates a p53-dependent antitumor checkpoint in hematopoiesis. *The Journal of experimental medicine*, 218(3).

Zhu X, et al. (2019) Noc4L-Mediated Ribosome Biogenesis Controls Activation of Regulatory and Conventional T Cells. *Cell reports*, 27(4), 1205.

Sharma MD, et al. (2018) Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors. *Immunity*, 48(1), 91.